drugset / Trial / NCT02876978
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to observe and confirm the safety, tolerance and cell pharmacokinetics of lentivirus-transduced CAR-GPC3 T cells (CAR-GPC3 T cells targeting GPC3)
Timeline
- Start
- 2016-03
- Primary completion
- 2017-10
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-GPC3 T Cells | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | CAR-GPC3 T Cells | Cell therapy | 2e+09 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |